Cilostazol-Aspirin Therapy Against Recurrent Stroke With Intracranial Artery Stenosis

Completed

Phase 3 Results N/A

Eligibility Criteria

Inclusion Criteria

- (1) Ischemic stroke after two weeks to six months from onset,
- (2) Responsible lesion identified on MRI,
- ( 3) Intracranial arterial stenosis >50% on MRA in the territory of responsible lesion,
- (4) Intracranial arterial stenosis in suproclinoid internal carotid arterry, M1 portion of midlle cerebral artery, or basilar artery,
- (5) Age of 45 to 85 years,
- (6) Able to visit out-patient clinic, and
- (7) Written informed consent obtained from patient or family.

Exclusion Criteria

- (1) Patients with potential cardiac embolic sources,
- (2) Patients receiving cilostazol,
- (3) Patients on warfarin treatment,
- (4) Patients in whom MRI cannot be perfomed,
- (5) Patients in whom PTA or bypass surgery is planned,
- (6) Patients with history of symptomatic intracranial hemorrhage, other hemorrhagic diseases (active peptic ulcer etc.), hemophilia or coagulation abnormalities,
- (7) Patients with hypersensitivity to cilostazol or aspirin,
- (8) Patients with congestive heart failure or uncontrollable angina pectoris,
- (9) Patients with thrombocytopenia (<100,000/mm3),
- (10) Patients with liver dysfunction (AST or ALT >100 IU/L),
- (11) Patients with renal dysfunction (Creatinin >2.0 mg/dl),
- (12) Patients who cannot to be followed up during the study period,
- (13) Patients who are enrolled in other clinical trials, and
- (14) Patients inadequate for this study by other reasons.